Effects of oncogenic p110α subunit mutations on the lipid kinase activity of phosphoinositide 3-kinase
Jeffrey D. Carson(GlaxoSmithKline (United States)), Lusong Luo(Beijing Biocytogen (China)), Ruth Lehr(South College), Dashyant Dhanak(Wilmington University), Robert H. Sinnamon(GlaxoSmithKline (United States)), Robert B. Kirkpatrick(Protein Express (United States)), Robert A. Copeland(Unknown), Peter J. Tummino(Intarcia Therapeutics (United States)), Kurt R. Auger(Research Triangle Park Foundation), Glenn Van Aller(GlaxoSmithKline (United States)), Richard R. Gontarek(South College)
Cited by 119
Related Papers
Identification of a Novel Inhibitor of Mitogen-activated Protein Kinase Kinase
|Journal of Biological Chemistry|1998|3k
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k